American Century Companies Inc. Has $3.29 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

American Century Companies Inc. lifted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 18.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 157,409 shares of the biopharmaceutical company's stock after purchasing an additional 24,395 shares during the period. American Century Companies Inc. owned 0.13% of Catalyst Pharmaceuticals worth $3,285,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of CPRX. abrdn plc bought a new position in Catalyst Pharmaceuticals during the fourth quarter valued at about $10,115,000. Raymond James Financial Inc. bought a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at approximately $6,887,000. Skandinaviska Enskilda Banken AB publ raised its stake in shares of Catalyst Pharmaceuticals by 74.3% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 731,900 shares of the biopharmaceutical company's stock valued at $15,421,000 after acquiring an additional 312,000 shares in the last quarter. Jane Street Group LLC lifted its holdings in Catalyst Pharmaceuticals by 245.4% in the 3rd quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company's stock worth $7,990,000 after purchasing an additional 285,564 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its position in Catalyst Pharmaceuticals by 5.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company's stock worth $61,681,000 after purchasing an additional 151,495 shares during the period. Institutional investors and hedge funds own 79.22% of the company's stock.

Remove Ads

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,904 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now directly owns 68,873 shares of the company's stock, valued at $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares of the company's stock, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on CPRX. Stephens reissued an "overweight" rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. HC Wainwright reissued a "buy" rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Robert W. Baird raised their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Finally, StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $32.29.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX traded up $0.60 on Friday, hitting $22.05. The company's stock had a trading volume of 1,108,745 shares, compared to its average volume of 1,142,484. The company has a market capitalization of $2.68 billion, a PE ratio of 18.69, a PEG ratio of 3.31 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $26.16. The company has a 50 day moving average price of $22.63 and a 200 day moving average price of $22.00.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.